AstraZeneca combines durable large-cap biopharma scale with broad-based growth across oncology, rare disease, and respiratory. The report rates AZN a Buy, with valuation the main debate and fair value anchored at $215.
AstraZeneca(AZN) stands out as a high-quality large-cap biopharma with three things moderate-risk investors usually want in the same package: durable commercial scale, visible medium-term growth, and lower stock volatility than the average growth name. The core case rests on hard numbers. Revenue reached $58.74B in 2025, up from $45.81B in 2023, while net income rose to $10.26B from $5.96B over the same span. In Q1 2026, revenue reached $15.288B and reported EPS was $1.99, with core EPS of $2.58. Management also reiterated FY2026 guidance for mid- to high-single-digit revenue growth and low double-digit core EPS growth at constant exchange rates.
The business is not leaning on a single blockbuster. Oncology revenue was $23.70B in 2025, Rare Disease revenue was $9.13B, and CVRM revenue was $12.76B. Tagrisso generated $7.25B in 2025, Imfinzi $6.06B, Ultomiris $4.72B, Farxiga $8.40B, and Calquence $3.52B. That breadth matters because Farxiga is already facing loss of exclusivity pressure, yet the company still posted 12.5% YoY revenue growth and 5.3% earnings growth on a trailing basis. In plain English, one franchise is aging, but several others are still climbing.
The main debate is valuation, not business quality. AZN trades at 27.77x trailing earnings, 18.02x forward earnings, and 1.42x PEG. Those are not bargain-bin multiples, but they are easier to defend when free cash flow reached $8.67B in 2025, ROE was 23.48%, operating margin was 27.94%, and analysts project EPS to rise from $11.66 in 2027 to $16.91 in 2030. For a balanced investor with a medium-term horizon, the stock looks more like a Buy on quality and pipeline depth than a deep-value entry. The fair value anchor in this report is $215.
AstraZeneca(AZN) is a global biopharmaceutical company headquartered in Cambridge, U.K., with 96,100 employees and a commercial footprint spanning more than 125 countries. The company focuses on prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, with BioPharmaceuticals centered on CVRM and Respiratory & Immunology. The U.S. is its largest market and represented 44% of total revenue as of Q3 2024.
The business model is classic big pharma at its best: discover or acquire differentiated medicines, protect them through patents and regulatory exclusivity, expand labels through clinical development, and scale globally through specialized commercial teams. What makes AZN different from a slower pharmaceutical incumbent is the mix. Gross margin was 81.9% in 2025, and the portfolio is increasingly weighted toward specialty medicines, biologics, oncology combinations, and rare disease therapies rather than mature primary-care products.
Management has set an Ambition 2030 target of $80B in total revenue. That target is not a slogan floating in the annual report for decoration. It is backed by a business that already grew from $37.42B in revenue in 2021 to $58.74B in 2025, plus a Q1 2026 update that showed continued momentum, 14 approvals in major regions since Q4 2025 results, and four positive high-value Phase III programs early in 2026.
Oncology is the crown jewel. Total Oncology revenue reached $23.70B in 2025, up from $17.15B in 2023 and $14.63B in 2022. In Q1 2026, oncology revenue grew 16% to $6.8B, with U.S. growth of 18% and Europe growth of 19%. Key brands are doing real work here, not just filling slides. Tagrisso generated $7.25B in 2025, Imfinzi $6.06B, Calquence $3.52B, Lynparza $3.28B, and Enhertu $1.80B on the reported segment view.
Rare Disease has become a major second engine since the Alexion acquisition. Rare Disease revenue reached $9.13B in 2025 versus $7.76B in 2023. In Q1 2026, the segment grew 15% to $2.4B. Ultomiris is now the lead asset at $4.72B in 2025, while Soliris declined to $1.84B as conversion and biosimilar pressure continue. Strensiq reached $1.68B in 2025 and grew 43% YoY in Q1 2026. This is a healthy transition story, with newer assets replacing older ones rather than leaving a hole in the floor.
BioPharmaceuticals is more mixed, which is exactly why it deserves attention. CVRM revenue was $12.76B in 2025, up from $10.59B in 2023, but Q1 2026 CVRM revenue fell 6% to $3.3B as Farxiga absorbed phased loss of exclusivity effects and China volume-based procurement pressure. Farxiga still produced $8.40B in 2025, so even modest erosion matters. Respiratory & Immunology is the cleaner growth offset. In Q1 2026, R&I revenue rose 7% to $2.3B, with Fasenra up 11% to $483M, Breztri up 13% to $353M, Tezspire up 34% to $303M, and Saphnelo up 24% to $171M.
The segment mix tells the larger story. AZN is shifting toward oncology, immunology, and rare disease while managing mature CVRM assets through the patent cycle. That is the right direction. Mature pharma companies that fail this handoff tend to look cheap right before they deserve to be. AZN is doing the opposite.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Tagrisso remains one of the most important assets in the portfolio. It generated $7.25B in 2025 and $1.8B in Q1 2026, up 5% YoY. Management said demand was strong across all stages of EGFR-mutated lung cancer in the U.S. and Europe, partly offset by higher-than-historic destocking in the U.S. The key point is that even with a temporary inventory headwind, the franchise still grew.
Imfinzi is arguably the more interesting medium-term asset because of its label expansion runway. It delivered $6.06B in 2025 and grew 30% in Q1 2026. Management cited contributions from newer launches including MATTERHORN in gastric, NIAGARA in bladder, and ADRIATIC in lung cancer, on top of established indications such as HIMALAYA and TOPAZ. The EMERALD-3 Phase III result adds another layer, with statistically significant and clinically meaningful progression-free survival improvement in hepatocellular carcinoma for the STRIDE plus lenvatinib arm.
Farxiga is still a flagship product by revenue, but it is now a flagship risk as well. The drug generated $8.40B in 2025, yet Q1 2026 revenue fell 3% to $2.2B. Management said generic manufacturers entered the U.S. market in April 2026 and noted phased LOE effects in established rest-of-world markets plus China VBP pressure. This is the cleanest example of why AZN’s diversification matters. A company built around one mega-brand would feel this as a fracture. AZN feels it as a headwind.
Ultomiris deserves equal attention. It generated $4.72B in 2025 and grew 18% in Q1 2026, driven by demand across indications including myasthenia gravis and PNH. The interim Phase III I CAN trial in IgAN met its primary endpoint, with statistically significant and clinically meaningful proteinuria reduction at week 34. Management said more than 560,000 patients are diagnosed with IgAN across the U.S., Japan, and EU5, and 60% would be eligible for treatment based on proteinuria. That is the kind of label expansion that can keep a rare disease franchise compounding.
Enhertu is another major growth lever, even though accounting structure means some economics flow through alliance revenue. Management said the brand is annualizing at $5B on an alliance view and grew 34% in Q1 2026. Early adoption in first-line HER2-positive breast cancer after DESTINY-Breast09 approval adds to the growth case. Between Tagrisso, Imfinzi, Ultomiris, and Enhertu, AZN has multiple flagship assets with different disease exposures and different growth curves.
AstraZeneca’s moat starts with R&D scale and breadth. Core R&D expense rose 8% in Q1 2026, active clinical trials increased 10%, and patient enrollment increased 30% YoY. The company is investing in cell therapies, T cell engagers, ADCs, and AI-enabled discovery partnerships with Tempus, Pathos, CSPC Pharmaceutical Group, and Nucs AI. This is not innovation theater. It is expensive, but it is also the engine behind future labels and future pricing power.
The pipeline is unusually broad for a company of this size. In early 2026 alone, management highlighted positive Phase III programs for tozorakimab and efzimfotase alfa, plus additional high-value readouts supporting Imfinzi and Ultomiris. Management also said the 2026 readout set supports risk-adjusted peak year revenue potential exceeding $10B. That does not mean every program will become a blockbuster. It does mean the company has enough shots on goal that one setback does not break the model.
Tozorakimab is a good example of differentiated science. Management said it is the first biologic to demonstrate efficacy in COPD in three pivotal trials that enrolled broad populations, with statistically significant and highly clinically meaningful reductions in annualized moderate-to-severe exacerbations in OBERON and TITANIA. The company described a dual-acting mechanism that inhibits both forms of IL-33 signaling. In pharma, mechanistic differentiation is the difference between a product and a commodity with a fancy logo.
Commercial breadth is another advantage. AZN can launch in oncology, respiratory, CVRM, and rare disease using established specialist channels across the U.S., Europe, China, and emerging markets. That matters because a great molecule without launch muscle is just a conference abstract with good manners.
AZN’s operating footprint is expanding alongside the pipeline. In Q1 2026, CapEx was $600M and included investment in a new ADC manufacturing facility in Singapore and a new manufacturing plant in Qingdao, China, for the inhaled respiratory portfolio. Management said CapEx is expected to increase by around one-third in 2026. That is a near-term drag on free cash flow conversion, but it also supports supply security and launch readiness in higher-value categories.
The company also announced a $3.5B U.S. investment in November 2024 to expand research and manufacturing by end-2026. That fits the broader industry push toward manufacturing localization and resilience. In biologics, ADCs, and specialty medicines, supply chain quality is not a back-office issue. It is part of the product.
Operational execution has improved materially over the past five years. Annual gross margin rose from 66.8% in 2021 to 81.9% in 2025, while operating income increased from $1.06B to $13.74B. In Q1 2026, gross margin was 82.5% and operating income was $4.25B on $15.29B of revenue. That kind of margin structure gives AZN room to fund R&D, absorb launch spending, and still expand earnings.
There are still execution costs. Q1 2026 deal payments totaled $1.1B, and management expects around $2.5B of milestone payments for the full year related to past transactions. Core finance expense is also expected to rise due to higher lease expense and lower interest income. Still, these are manageable frictions inside a business generating $14.57B of annual operating cash flow in 2025.
AZN operates inside a large and steadily growing end market. The global pharmaceuticals market was estimated at $1.78T in 2025 by one industry source, with growth toward $2.62T by 2031, implying a 6.73% CAGR. North America represented 41.23% of the market in 2025, while Asia-Pacific is expected to be the fastest-growing major region. That backdrop supports AZN’s geographic mix, especially its large U.S. presence and continued investment in China and emerging markets.
The most attractive pockets of the market remain oncology, rare disease, and specialty biologics. FDA data shows biologics account for 5% of U.S. prescriptions but 51% of total drug spending as of 2024. That concentration of value helps explain why AZN is leaning into oncology, immunology, ADCs, and rare disease rather than trying to defend every mature primary-care brand to the last molecule.
AZN’s own strategic target also frames the opportunity. Management is aiming for $80B in revenue by 2030, versus $58.74B in 2025. Analyst estimates align with meaningful continued growth, with revenue projected at $67.90B in 2027, $72.29B in 2028, $77.63B in 2029, and $83.12B in 2030. That trajectory implies the company is not relying on a heroic macro backdrop. It is relying on share gains, label expansions, and pipeline conversions in markets that are already large.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
AZN sells primarily to healthcare systems, hospitals, specialty clinics, physicians, and distributors rather than directly to consumers. In practice, the real customer stack is more complex: prescribers choose, payers negotiate, regulators constrain, and patients live with the result. That is why clinical differentiation matters so much in this industry. A drug that clearly improves outcomes has a much stronger path through reimbursement friction.
The company’s customer mix skews toward specialty care. Oncology products such as Tagrisso, Imfinzi, Calquence, and Enhertu are prescribed by oncologists in hospital and specialty settings. Rare disease products such as Ultomiris and Strensiq serve smaller, high-touch patient populations through specialist networks. Respiratory and immunology products such as Fasenra, Tezspire, Breztri, and Saphnelo sit in a mix of specialty and chronic-care channels.
This customer profile is favorable for margins and retention. Specialty medicines tend to face lower substitution risk than mass-market primary-care drugs, though they face more reimbursement scrutiny. AZN’s high gross margin of 81.5% and operating margin of 27.94% reflect that mix. The tradeoff is that every launch must clear a high evidence bar. In this business, the customer is not always right, but the payer always sends the invoice.
AZN competes against the largest and best-capitalized drugmakers in the world. In oncology, major rivals include Merck, Roche, Bristol Myers Squibb, Pfizer, Novartis, Johnson & Johnson, AbbVie, and others. In Respiratory & Immunology, GSK, Sanofi, Regeneron, and Novartis are important competitors. In CVRM, the field includes Eli Lilly, Novo Nordisk, Bayer, Boehringer Ingelheim, and J&J depending on indication. In rare disease, Alexion’s legacy competitors include Vertex, BioMarin, Amgen, and Sanofi in selected markets.
The peer comparison dataset failed, so the cleanest relative read comes from business mix and valuation signals that are available. AZN’s forward P/E of 18.02 and PEG of 1.42 place it in the zone of a premium large-cap pharma name rather than a distressed incumbent. That premium is supported by faster growth than many mature pharma peers, but it is still a premium. Investors are paying for pipeline depth, not just current earnings.
Where AZN appears strongest is breadth. Many large pharma companies have one dominant franchise and a few supporting acts. AZN has multiple growth engines across lung cancer, immuno-oncology, rare disease, respiratory biologics, and select CVRM assets. That lowers single-asset risk. Where AZN is more vulnerable is in categories with heavy competition and reimbursement pressure, especially as mature products like Farxiga move through LOE.
For AZN, macro risk is less about GDP prints and more about pricing policy, patent cycles, regulation, and cross-border manufacturing. FDA actions in 2025 to accelerate biosimilar development and simplify generic pathways point to a more pro-competition environment. That is a direct headwind for mature brands and a long-term pressure point for biologics pricing.
China remains important and complicated. In Q1 2026, management said China revenue increased 2%, with VBP implementation affecting Farxiga, Lynparza, and roxadustat growth. At the same time, management said it remained confident in China based on positive 2026 NRDL outcomes. That is the usual China tradeoff in pharma: large volume opportunity, thinner pricing power, and policy that can change the economics quickly.
The U.S. is the biggest strategic market. It represented 44% of total revenue as of Q3 2024, and AZN is investing $3.5B in U.S. R&D and manufacturing by end-2026. That should strengthen domestic supply resilience and keep the company close to the world’s deepest commercial pharma market. It also increases exposure to U.S. pricing and reimbursement policy, which is where most of the global industry’s political weather forms first.
The good news is that AZN’s low beta of 0.214 suggests the stock has behaved defensively relative to the broader market. That does not make it immune to policy shocks, but it does make it more suitable for moderate-risk investors than many biotech names that move like a trial result with a ticker attached.
Net debt stood at $53.01B in 2025, but the company still generated $8.67B of free cash flow and maintained a 1.79 current ratio.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue climbed to $58.74B in 2025 from $45.81B in 2023, while operating margin held at 27.94% and gross margin reached 81.9%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is guiding for mid- to high-single-digit revenue growth and low double-digit core EPS growth in FY2026, with analysts projecting EPS to rise from $11.66 in 2027 to $16.91 in 2030.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →AZN trades at 27.77x trailing earnings, 18.02x forward earnings, and 1.42x PEG, which is reasonable for a company with 23.48% ROE and a deep late-stage pipeline.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value anchor is $215, with upside supported by oncology and rare disease growth but tempered by Farxiga LOE pressure and a premium multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →AstraZeneca(AZN) is one of the more compelling large-cap pharma names for a medium-term investor who wants growth without stepping into the binary chaos of smaller biotech. The company has scale, strong profitability, improving balance sheet metrics, rising free cash flow, and a pipeline that is producing real clinical results rather than vague aspirations. Revenue has compounded sharply since 2021, and Q1 2026 showed that momentum remains intact.
The risk is real but understandable. Farxiga is moving through LOE, China pricing can pressure growth, and the company is spending aggressively on R&D, manufacturing, and launches. Those are not trivial issues. But the broader portfolio is doing enough to offset them, and that is the central point. AZN is not trying to outrun a patent cliff with optimism alone. It is doing it with Tagrisso, Imfinzi, Ultomiris, Enhertu, Calquence, Tezspire, Breztri, and a fresh set of late-stage assets.
For moderate-risk investors, the stock looks best accumulated below the report’s fair value estimate of $215, with particularly attractive risk-reward closer to $185. Above $245, discipline matters more. For now, the business quality is strong enough, the pipeline is broad enough, and the valuation is reasonable enough to support a Buy.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
AstraZeneca PLC (AZN) rises after a new kidney disease partnership with CSPC Pharmaceutical Group sparked investor interest. The large-cap drugmaker’s move reflects confidence in its pipeline strategy, with the stock trading on solid volume and supported by a broad, diversified business model.
AstraZeneca PLC (AZN) rises 6.5% after announcing a kidney disease collaboration with CSPC Pharmaceutical Group worth up to $1.77B. The move also reflects broader defensive buying in healthcare as investors reward AstraZeneca’s pipeline expansion and steady earnings execution.
ATII Holdings is going public through a merger with Archimedes Tech SPAC Partners II Co., with the combined company expected to trade on Nasdaq under NANO. The bull case is a domestic semiconductor-and-battery platform with a $100 million PIPE; the bear case is classic de-SPAC dilution and redemption risk.